Anthem Biosciences Limited, a Bengaluru-based CRDMO (Contract Research, Development, and Manufacturing Organization), made a stellar debut on the Indian stock exchanges on July 21, 2025. The IPO, which was entirely an Offer for Sale (OFS) worth ₹3,395 crore, received overwhelming investor interest, with a subscription rate of 67.42 times overall.
IPO Listing Details
Listing Date: July 21, 2025
Issue Price: ₹570 per share
Listing Price: ₹723.10 on BSE and ₹723.05 on NSE
Listing Gain: Approx. 26.85% over issue price
Market Capitalization Post Listing: ₹40,610 crore
The IPO was backed by strong anchor investor participation, including global giants like ADIA, Amundi Funds, and domestic mutual funds such as HDFC MF and ICICI Prudential MF.
Anthem Biosciences Share Price Performance
As of 12:40 PM IST on July 21, Anthem Biosciences was trading at ₹729.95, reflecting a 28.06% gain from its IPO price. The stock showed resilience and investor confidence, with intraday highs reaching ₹746.70.
Share Price Target for 2025
Based on current momentum, expert analysis, and grey market premium trends:
Estimated Target Range for 2025: ₹713 to ₹749
Grey Market Premium (GMP): ₹177–₹179 ahead of listing
Expected Listing Price (Pre-listing estimate): ₹747
Brokerages remain optimistic about Anthem’s long-term prospects, citing its niche positioning in the CRDMO space, robust financials, and global client base. Some analysts suggest a short-term target of ₹900 and a long-term potential of ₹1,000+, depending on earnings growth and margin sustainability.
Company Overview
Founded in 2006, Anthem Biosciences specializes in fermentation-based APIs, biologics, and drug development services. It serves over 675 clients across 44 countries, with a portfolio of 242 active projects and a strong innovation pipeline.